Navigation Links
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Date:3/10/2009

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

In a study, sponsored by the National Institutes of Health and conducted by the Eastern Cooperative Oncology Group (ECOG) titled, "Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study," researchers looked at 311 patients with stable or responding disease after CVP therapy. The patients were randomly assigned to observation only or a maintenance rituximab (MR) 375 mg/square meter once per week for 4 weeks every 6 months for 2 years. Results are the first phase III data showing patients with untreated indolent lymphoma can be given (MR) after chemotherapy with minimal toxicity to prevent relapse.

"Low grade lymphoma is very treatable, with patients living many years on the average," says Howard Hochster, M.D. professor of medicine and clinical pharmacology at NYU School of Medicine and director of gastrointestinal oncology and early drug development at the NYU Cancer Institute. "But no one treatment to date has been able to show benefit on long term survival. This reasonably non-toxic antibody can improve disease free survival by several years and possibly effect overall survival. In this group of patients, even 10 years of observation is a little too soon to show survival benefits, but the trend is present."

An improved disease response was seen in 22% of rituximab-treated patients versus just 7% of control subjects. Toxic effects were minimal in both groups. Three year progression-free survival was also higher in the MR group: 68% vs. 33% in controls. In the sub group of 282 patients with follicular lymphoma, the corresponding rates were 64% and 33%. With more than ten years follow-up, the patients receiving MR went nearly 5 years on average before relapse, compared with 1.9 years without .

According to the National Cancer Institute, lymphoma is a disease in which malignant cancer cells form in the lymph system. Indolent lymphoma includes several sub-types of lymphoma that tend to grow and spread slowly, and has few symptoms. It's also called low-grade lymphoma.

The anti-CD20 monoclonal antibody, rituximab was approved for use in follicular lymphoma and indolent lymphoma in 1997 for those no longer responding to chemotherapy. In this setting, the objective response rate was 48% and the agent had rare serious adverse effects, generally limited to infusional toxicity. On the basis of earlier trials, the E1496 study, is the first to test rituximab to maintain response to chemotherapy in indolent lymphoma. Observations from this most recent study add to a substantial body of evidence that the combination of rituximab with chemotherapy is a new standard for patients with indolent lymphoma who require treatment.

The National Cancer Institute funded this multi-center, national trial through ECOG, which began in 1997. Trial centers included the NYU Langone Medical Center in New York City, the Dana Farber Cancer Institute in Boston, Columbia Cancer Agency in Vancouver, the Mayo Clinic in Rochester, Northwestern University in Chicago, Stanford University in Stanford and the University of Maryland in Baltimore.

"This study has led to a new FDA indication for the use of rituximab as maintenance therapy in patients with indolent lymphoma," states Dr. Hochster.


'/>"/>

Contact: Dorie Klissas
dorie.klissas@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Study Links Blood Type and Pancreatic Cancer
2. New study identifies risk factors in severity of flat head syndrome in babies
3. New Study Shows That One-Third of Shelter Youth Have Been Institutionalized; Almost One-Half Suffered Violence in the Home
4. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
5. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
6. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
7. Study Shows 80% of Adults with Peripheral Arterial Disease Go Undiagnosed
8. Study finds pay for performance stimulates changes in medical practice
9. Study: Doctor-patient conversations at end of life associated with lower medical expenses
10. Study tests reliability of more accurate measure of patient pain
11. New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 ... ... healthcare that considers individuals’ genetic characteristics and the physical and behavioral worlds ... work in sync. In personalized medicine, diagnosing an individual’s disease depends on ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... today announced it has been included by Gartner, Inc. in the Contact Center ... range of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration ...
(Date:5/31/2016)... ... 2016 , ... Twenty years ago it was revolutionary: enabling the people who ... voices they hear. But this approach has proven transformative, both for people who hear ... credibility and now is used around the world, but it still lags in the ...
(Date:5/31/2016)... ... ... DDL, Inc. announced today it has expanded the scope of its ISO/IEC ... and ISO 594-2 testing for conical (Luer) fittings. , A conical Luer fitting ... (e.g. a syringe and hypodermic needle) that carry small volumes of fluids. There are ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only ... the industry as a whole. On June 2, Northbound CEO Mike Neatherton and COO ... (WCSAD) and presenting the opening plenary on “Leadership: The Journey to Authenticity” with Onsite ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... VALLEY COTTAGE, New York , May 31, 2016 ... traction as an essential ingredient in food, cosmetics and ... 2016 end, representing revenues worth US$ 1.6 Bn. ... vera gels, cosmetics products, juices, and yogurts will continue ... health and wellness trend will also boost positive sentiment ...
(Date:5/31/2016)... May 31, 2016 , Isansys  Lifecare, ... its Patient Status Engine wireless patient monitoring platform, as it ... Germany , Scotland and ... 2 nd generation system, launched earlier this year, is now ... , , This new technology significantly enhances ...
(Date:5/30/2016)... , May 30, 2016 ... report "Healthcare Biometrics Market by Technology (Single-factor ... Multifactor, Multimodal), Application (Workforce Management), End User ... 2021", published by MarketsandMarkets, the market is ... 2021 from USD 1,182.6 Million by 2016, ...
Breaking Medicine Technology: